Connery, Lisa
for the SURMOUNT-4 Investigators
6 papers on CoChat
Most cited papers
- Verified
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 3,838
- Verified
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA
Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes
Cited by 860
- Verified
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 684
- Verified
PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 493
- Verified
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 478
- Verified
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 351
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free